Our in silico analysis shows that the ER+/HER2− Basal subtype is very different from the ER+/HER2− Luminal subtype—and sometimes closer to the ER− Basal subtype—in terms of response and/or potential vulnerability to systemic therapies of BC. Here, ESR1 is linked to breast cancer.